Prosecution Insights
Last updated: April 19, 2026
Application No. 18/318,914

N -SUBSTITUTED 4-(1,3-ARYLOXAZOLO-2-YL)PHENYL COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

Non-Final OA §102§112
Filed
May 17, 2023
Examiner
COLEMAN, BRENDA LIBBY
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche, Inc.
OA Round
1 (Non-Final)
75%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
90%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allow Rate
1201 granted / 1604 resolved
+14.9% vs TC avg
Strong +15% interview lift
Without
With
+15.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
46 currently pending
Career history
1650
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
5.8%
-34.2% vs TC avg
§102
16.9%
-23.1% vs TC avg
§112
52.3%
+12.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1604 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-23 are pending in this application. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7, 11 and 13-23 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The following reasons apply: Claims 1, 2 and claims dependent thereon are vague and indefinite in that it is not known what is meant by the second occurrence of “3-methyloxetan-3-yl” which appears in line 2 and again in lines 9-10 in the definition of R1. Claim 11 recites the limitation "2-methyl-oxazole" with respect to the species 45 (4th species on page 67) and species 81 (5th species on page 68) variable R1. There is insufficient antecedent basis for this limitation in the claim. Claims 14 and 21 are substantial duplicates of claim 1, as the only difference is a statement of intended use, which does not limit the scope of the claim under the broadest reasonable interpretation and therefore is not given material weight. Note In re Tuominen 671 F.2d 1359, 1360, 213 USPQ 89, 90 (C.C.P.A. 1982). Claims 15-20 provide for the use of the compound of claim 1, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-10 and 13-22 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Cuervo et al., WO 2020/077024. Cuervo teaches the compounds, compositions, process of preparing and method of use of the compounds of formula (I) where A1 is CH, A2 is CH, A3 is CCl, A4 is CH, R1 is cyclopropyl as set forth in example 25. Claim(s) 1-7, 13-22 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Sakaitani et al., JP 2018087173. Sakaitani teaches the compounds, compositions, process of preparing and method of use of the compounds of formula (I) where A1 is CH or N, A2 is CH or CF, A3 is CH or CF, A4 is CH, R1 is 3-pyridyl as set forth in example 4-7, 4-26 and 4-27. Claim(s) 1-10 and 14-22 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Registry No. 354157-03-2, 842116-39-6, 1016843-58-5, 1144472-04-7, 1193002-3-3 and 1193002-21-9 as follows: 354157-03-2 PNG media_image1.png 200 400 media_image1.png Greyscale 31 Aug 2001; 842116-39-6 PNG media_image2.png 200 400 media_image2.png Greyscale 04 Mar 2005; 1016843-58-5 PNG media_image3.png 200 400 media_image3.png Greyscale 24 Apr 2008; 1144472-04-7 PNG media_image4.png 200 400 media_image4.png Greyscale 08 May 2009; 1193002-3-3 PNG media_image5.png 200 400 media_image5.png Greyscale 20 Nov 2009; and 1193002-21-9 PNG media_image6.png 200 400 media_image6.png Greyscale 20 Nov 2009. Claim Objections Claim 12 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim 22 is objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must be stated in the alternative. See MPEP § 608.01(n). Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRENDA L COLEMAN whose telephone number is (571)272-0665. The examiner can normally be reached Mon-Fri 10-6 (flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey H. Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRENDA L COLEMAN/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

May 17, 2023
Application Filed
Oct 06, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595228
PROCESS FOR SYNTHESIZING TRIARYLMETHANE SULFONE COMPOUNDS
2y 5m to grant Granted Apr 07, 2026
Patent 12595259
AMINOPYRIDINE COMPOUND
2y 5m to grant Granted Apr 07, 2026
Patent 12590081
FUSED IMIDAZOLE DERIVATIVES, PREPARATION METHOD AND MEDICINAL USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12575569
METHODS OF CONTROLLING OR PREVENTING INFESTATION OF RICE PLANTS BY THE PHYTOPATHOGENIC MICROORGANISM GIBBERELLA FUJIKUROI
2y 5m to grant Granted Mar 17, 2026
Patent 12577262
FUNCTIONALIZED GOLD CARBENE NAPTHAQUINONE COMPLEXES FOR USE IN THE TREATMENT OF CANCER
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
75%
Grant Probability
90%
With Interview (+15.4%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1604 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month